文献速递精神分裂症与精神病性障碍

芬兰首发精神分裂症复发预防抗精神病药治疗策略的比较效果:一项基于人群的队列研究

Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study.
PubMed 文献 · Lancet Psychiatry · 2025-01-01

该研究纳入1996至2014年间芬兰全国出院登记中≤45岁、首发精神分裂症住院后5年内复发且入院前一年未用抗精神病药者3000例,分析首次复发前后30天治疗策略与2年内第二次复发风险的关系。与继续原非氯氮平口服抗精神病药单药治疗相比,换用氯氮平与最低的二次复发风险相关(aHR 0.66,95%CI 0.49-0.89),换用另一种非氯氮平口服药单药或停用抗精神病药未见获益。

要点

  • 首次复发前45.5%未用抗精神病药,32.4%用非氯氮平口服药单药。
  • 换用氯氮平者二次复发率57.1%,继续原口服药单药者73.2%。
  • 换用另一种非氯氮平口服药单药(aHR 0.99)与停用抗精神病药(aHR 1.07)均未见获益证据。

核心结论

  • 在尽管使用非氯氮平口服抗精神病药仍出现首次精神病性复发的首发精神分裂症患者中,继续原抗精神病药模式或换用另一种非氯氮平口服药在预防复发方面未显示获益证据,提示应换用氯氮平。

研究设计与样本

  • 基于人群的队列研究,纳入芬兰全国出院登记中1996年至2014年间住院且随后复发的≤45岁首发精神分裂症个体。
  • 纳入初始住院前一年内未服用抗精神病药且出院后5年内复发者,分析首次复发住院前30天及出院后30天治疗策略。
  • 采用Cox回归模型分析首次复发后2年内第二次复发风险的调整风险比(aHR),随访至死亡或数据链接结束(2017年12月31日)。

主要发现

  • 1996年1月31日至2017年12月31日间共3000例首次精神病性复发者纳入分析,平均年龄30.0岁(SD 7.6),女性1069例(35.6%),男性1931例(64.4%)。
  • 2148例(71.7%)在2年内出现第二次复发。
  • 首次复发前,未使用抗精神病药者1366例(45.5%),使用非氯氮平口服抗精神病药单药治疗者973例(32.4%)。
  • 与继续首次复发前相同治疗策略相比,换用氯氮平与继续任何非氯氮平口服抗精神病药单药治疗相比,第二次复发风险aHR为0.66(95%CI 0.49-0.89),复发率在继续口服非氯氮平抗精神病药单药治疗组为73.2%,换用氯氮平组为57.1%。
  • 换用另一种非氯氮平口服抗精神病药单药治疗aHR为0.99(95%CI 0.76-1.28),换用抗精神病药非使用aHR为1.07(95%CI 0.80-1.42)。

关键数值与推荐

  • 换用氯氮平与继续非氯氮平口服抗精神病药单药治疗相比,第二次复发aHR 0.66(95%CI 0.49-0.89),复发率57.1% vs 73.2%。
  • 换用另一种非氯氮平口服抗精神病药单药治疗aHR 0.99(95%CI 0.76-1.28)。
  • 换用抗精神病药非使用aHR 1.07(95%CI 0.80-1.42)。

临床怎么用

  • 作者认为,对于使用非氯氮平口服抗精神病药仍出现首次精神病性复发的首发精神分裂症患者,继续原抗精神病药模式或换用另一种非氯氮平口服药未显示预防复发的获益证据,提示应换用氯氮平。
  • 作者指出,该发现与现有关于氯氮平可降低死亡风险的知识共同挑战了当前将氯氮平作为三线治疗的指南推荐,后者导致氯氮平启用长期延迟的治疗实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The best pharmacological treatment practices for relapse prevention in patients with first-episode schizophrenia are unclear. We aimed to assess different treatment strategies used before and after the first relapse, and their associations with subsequent relapse risk. METHODS: In this population-based cohort study, we enrolled individuals (aged ≤45 years) with first-episode schizophrenia who were hospitalised and subsequently relapsed between 1996 and 2014 from the nationwide Finnish Hospital Discharge Register. Individuals who had not been taking antipsychotics within the year preceeding initial hospitalisation and who had a relapse within 5 years of discharge were included in the analyses. Treatment strategies were assessed during the 30 days before hospitalisation for the first relapse and 30 days after discharge and were categorised as either long-acting injectable, clozapine, non-clozapine oral antipsychotic monotherapy, non-clozapine oral antipsychotic polypharmacy, and antipsychotic non-use. Adjusted hazard ratios (aHRs) of the risk of second relapse based on treatment type were analysed with Cox regression models for 2 years after the first relapse, or until death or end of data linkage (Dec 31, 2017). People with lived experience of schizophrenia were not involved in the research and writing process. FINDINGS: Between Jan 31, 1996 and Dec 31, 2017, 3000 individuals had their first psychosis relapse and were eligible for analysis. Mean age was 30·0 years (SD 7·6), 1069 (35·6%) of patients were women and 1931 (64·4%) men. No ethnicity data were available. 2148 (71·7%) had a second relapse within 2 years. Before first relapse, most individuals were either not using antipsychotics (n=1366 [45·5%]), or were using non-clozapine oral antipsychotic monotherapy (n=973 [32·4%]). Compared with continuing the same treatment strategy used before the first relapse, switching to clozapine was associated with the lowest risk of second relapse compared with continuing any non-clozapine oral antipsychotic monotherapy (aHR 0·66, 95% CI 0·49-0·89; relapse rate 73·2% with oral non-clozapine antipsychotic monotherapy continuation vs 57·1% with switch to clozapine). Switching to another non-clozapine oral antipsychotic monotherapy (0·99, 0·76-1·28) was approximately as unhelpful in preventing the next relapse as switching to antipsychotic non-use (1·07, 0·80-1·42). INTERPRETATION: In patients with first-episode schizophrenia having their first psychosis relapse despite use of non-clozapine oral antipsychotics, continuation with the same antipsychotic modality or switch to another non-clozapine oral antipsychotic did not show evidence of being beneficial in relapse prevention, suggesting that clozapine should be started instead. This finding, together with existing knowledge of decreased risk of mortality associated with clozapine, challenges current treatment guidelines that recommend clozapine as a third-line treatment, resulting in treatment practices characterised by long delays to clozapine initiation. FUNDING: Sigrid Jusélius Foundation.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Taipale H, Tanskanen A, Howes O, et al. Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study. Lancet Psychiatry. 2025. PMID: 39848730. doi:10.1016/S2215-0366(24)00366-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。